Related references
Note: Only part of the references are listed.Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
S. Petersenn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study
Jan-Hendrik Buhk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Pituitary somatostatin receptor signaling
Anat Ben-Shlomo et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2010)
Medical Therapy of Acromegaly Efficacy and Safety of Somatostatin Analogues
Richard A. Feelders et al.
DRUGS (2009)
Successful use of weekly pegvisomant administration in patients with acromegaly
C. E. Higham et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
ACROSTUDY: the first 5 years
Peter J. Trainer
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Medical Therapy in Patients with Acromegaly: Predictors of Response and Comparison of Efficacy of Dopamine Agonists and Somatostatin Analogues
M. Sherlock et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas
Sophie Vallette et al.
PITUITARY (2009)
Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required
M. Kars et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly
V. J. Moyes et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Follow-up of pituitary tumor volume in patients with acromegaly treated with pegvisomant in clinical trials
Camilo Jimenez et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Cabergoline and the risk of valvular lesions in endocrine disease
Patrizio Lancellotti et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease
Ammar Wakil et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Growth hormone excess and the development of growth hormone receptor antagonists
C. E. Higham et al.
EXPERIMENTAL PHYSIOLOGY (2008)
Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia
F. Bogazzi et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2008)
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
Robert D. Murray et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Increased prevalence of tricuspid regurgitation in patients with Prolactinomas chronically treated with cabergoline
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial
Sven M. Carlsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Mortality in acromegaly: A meta analysis
O. M. Dekkers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Management of acromegaly: Is there a role for primary medical therapy?
Zachary M. Bush et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2008)
Long-term efficacy and safety of combined treatment of somatostatin analogs and Pegvisomant in acromegaly
Sebastian J. C. M. M. Neggers et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice
A. Pokrajac et al.
CLINICAL ENDOCRINOLOGY (2007)
Dopamine agonists and the risk of cardiac-valve regurgitation
Rene Schade et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Valvular heart disease and the use of dopamine agonists for Parkinson's disease
Renzo Zanettini et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly
B. Steffin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Drug-induced hepatitis in an acromegalic patient during combined treatment with pegvisomant and octreotide long-acting repeatable attributed to the use of pegvisomant
J Feenstra et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
First-line octreotide-LAR therapy induces tumour shrinkage and controls hormone excess in patients with acromegaly: results from an open, prospective, multicentre trial
A Colao et al.
CLINICAL ENDOCRINOLOGY (2006)
Efficacy of 12-month treatment with the GH receptor antagonist pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on lGF-I levels, tumor mass, hypertension and glucose tolerance
A Colao et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis
H Biering et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Re-evaluation of the efficacy of the association of cabergoline to somatostatin analogues in acromegalic patients
B Gatta et al.
CLINICAL ENDOCRINOLOGY (2005)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
P Jaquet et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Combined therapy with somatostatin analogues and weekly pegvisomant in active acromegaly
J Feenstra et al.
LANCET (2005)
Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly
D Selvarajah et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly
JS Bevan
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly
S Jehle et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease
G Van Camp et al.
LANCET (2004)
Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly
J Ayuk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients
J van der Hoek et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
R Cozzi et al.
CLINICAL ENDOCRINOLOGY (2004)
Determinants of survival in treated acromegaly in a single center: Predictive value of serial insulin-like growth factor I measurements
NR Biermasz et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2004)
Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment
Roberto Baldelli et al.
CLINICAL ENDOCRINOLOGY (2003)
Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: Predictive value of short-term results?
R Cozzi et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Preoperative lanreotide treatment for GH-secreting pituitary adenomas:: effect on tumour volume and predictive factors of significant tumour shrinkage
T Lucas et al.
CLINICAL ENDOCRINOLOGY (2003)
Octreotide long-acting release (LAR) - A review of its use in the management of acromegaly
K McKeage et al.
DRUGS (2003)
Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly
C Beauregard et al.
CLINICAL ENDOCRINOLOGY (2003)
Primary medical therapy for acromegaly: An open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size
JS Bevan et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Long-term effects of lanreotide SR and octreotide LAR (R) on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly
G Amato et al.
CLINICAL ENDOCRINOLOGY (2002)
Efficacy and safety of the new 60-mg formulation of the long-acting somatostatin analog lanreotide in the treatment of acromegaly
MR Ambrosio et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2002)
Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly
P Caron et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitary adenomas
M Losa et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Effects of preoperative octreotide treatment on different subtypes of 90 GH-secreting pituitary adenomas and outcome in one surgical centre
T Abe et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2001)
Somatostatin receptor-specific analogs: Effects on cell proliferation and growth hormone secretion in human somatotroph tumors
DC Danila et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly
P Chanson et al.
CLINICAL ENDOCRINOLOGY (2000)
Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients
JA Verhelst et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2000)
Two-year follow-up of acromegalic patients treated with slow release lanreotide (30 mg)
R Baldelli et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs
VS Herman-Bonert et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Human somatostatin receptor subtypes in acromegaly: Distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes
P Jaquet et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2000)
Share Paper
